Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sevim Peri Aytaç"'
Publikováno v:
Turk J Pharm Sci
OBJECTIVES: Dexketoprofen is a non-steroidal analgesic/anti-inflammatory drug and its trometamol salt is extensively preferred in mild or moderate pain due to its rapid onset of relief. A new formulation of 36.9 mg of dexketoprofen trometamol (equiva
Publikováno v:
Acta Medica. 53:251-260
Objective: Polypharmacology, interaction of one drug with multiple targets, emerged as an effective approach in drug discovery and development. Bioinformatics and cheminformatics methods are essential tools for determination of polypharmacological pr
Autor:
Fırat YERLİKAYA, Aslihan ARSLAN, Özlem ATİK, Seda KOZAN, Ahmet PARLAK, Meltem ÖZEL KARATAŞ, Onursal SAĞLAM, Sevim Peri AYTAÇ
Publikováno v:
Fabad Journal of Pharmaceutical Sciences.
A new oral formulation of cefdinir, Cefdinir 600 mg Tablets has been developed and in this study, its relative bioavailability has been compared with another oral solid dosage form, Cefdinir 300 mg Capsules, which is already on the market. An open-la
Autor:
Fırat YERLİKAYA, Aslıhan ARSLAN, Özlem ATİK, Seda KOZAN, Ahmet PARLAK, Meltem ÖZEL KARATAŞ, Onursal SAĞLAM, Sevim Peri AYTAÇ
Publikováno v:
Hacettepe University Journal of the Faculty of Pharmacy.
A new liquid oral formulation of cefdinir has been developed and a bioequivalence study was conducted. This single-center study was designed as an open-label, randomized, two-period, cross-over trial, and was performed with healthy males under fastin
Publikováno v:
Powder Diffraction. 32:271-278
The 3-[1-(6-methoxy-2-naphtyl)ethyl]-6-(2,4-dichlorophenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine, C23H18Cl2N4OS compound was synthesized, as a member of the family of novel potential anticancer agents. The structure of the title compound was ch
Publikováno v:
Powder Diffraction. 32:279-289
Two novel compounds, 3-[1-(2-fluoro-4-biphenyl)ethyl]-6-(4-fluorophenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (C23H16F2N4S) (1) and 3-[1-(2-fluoro-4-biphenyl)ethyl]-6-(4-chlorophenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (C23H16ClFN4S) (2), hav
3-[1-[4-(2-Methylpropyephenyl] ethyl]-6-(4-fluorophenyl)-1,2,4-triazolo [3,4-b] -1,3,4-thiadiazole (C21H21FN4S) has been synthesized as a member of a series of triazolothiadiazoles having NSAIDs moieties with cytotoxic activity. The crystal structure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::989cbf67913742e072016b04e3c15acc
https://hdl.handle.net/11491/6826
https://hdl.handle.net/11491/6826
Publikováno v:
Letters in Drug Design & Discovery. 9:204-212
Publikováno v:
Structural Chemistry. 21:795-802
In this study, two novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivatives, 3-[2-(4-methoxyphenyl)ethyl]-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (compound 1) and 3-[2-(3,4,5-trimethoxyphenyl)ethyl]-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,
Publikováno v:
Archiv der Pharmazie. 342:291-298
In this study, the synthesis of a new series of 3,6-disubstituted-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazine 1a-4c compounds derived from 4-amino-3-substituted-1,2,4-triazole-5-thiones 1-4 is described. All of the synthesized compounds were screened